High Grade Serous Carcinoma Clinical Trial
Official title:
A Phase II Trial to Evaluate the Efficacy of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer
This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade serous carcinoma without BRCA mutation among patients with platinum-resistant recurrent ovarian cancer.
Subjects are dosed with Bortezomib and PLD for a maximum of 6 cycles of 4 weeks. The response rate is evaluated with CT according to RECIST criteria ver 1.1. The efficacy and safety of the drug are assessed at the time of recurrence, at the time of death, or after 24 months after the end of the study drug administration. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05537844 -
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
|
||
| Recruiting |
NCT05358639 -
Combination of Olaparib and Navitoclax in Women With HGSC and TNBC
|
Phase 1 | |
| Recruiting |
NCT03738319 -
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer
|
||
| Recruiting |
NCT05080556 -
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
|
Phase 2 | |
| Recruiting |
NCT03462342 -
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
|
Phase 2 | |
| Withdrawn |
NCT05390021 -
PET/MRI in Endometrial Cancer
|
N/A | |
| Terminated |
NCT04598321 -
BrUOG 390: Neoadjuvant Treatment With Talazoparib
|
Phase 1 | |
| Completed |
NCT05490407 -
Role of the ATP7A Transporter in Ovarian Cancer
|
N/A | |
| Recruiting |
NCT04846933 -
Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
|
||
| Completed |
NCT03593681 -
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
|
||
| Terminated |
NCT03824704 -
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
|
Phase 2 |